Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers may leads to lower cardiovascular mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
It is very uncertain whether beta‐blockers changes heart failure hospitalisation (RR) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
All‐cause mortality at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
Beta‐blockers showed no clear difference in all‐cause mortality at 'less than 3 months' compared with placebo or no intervention (high certainty).
1 finding from 1 review
MACE · patients with suspected or diagnosed myocardial infarction
It is very uncertain whether beta‐blockers changes MACE (major adverse cardiovascular event) at maximum compared with placebo or no intervention (very low certainty).
2 findings from 1 review
Quality of life at maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Angina · patients with suspected or diagnosed myocardial infarction
It is very uncertain whether beta‐blockers changes angina at maximum compared with placebo or no intervention (very low certainty).
2 findings from 1 review
Cardiovascular mortality · patients with suspected or diagnosed myocardial infarction
Beta‐blockers probably leads to lower cardiovascular mortality at maximum compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
Myocardial infarction · patients with suspected or diagnosed myocardial infarction
Beta‐blockers showed no clear difference in myocardial infarction at maximum compared with placebo or no intervention (low certainty).
2 findings from 1 review
Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · patients with suspected or diagnosed myocardial infarction
Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total mortality
Beta‐blockers showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
Beta‐blockers showed no clear difference in withdrawal due to adverse effect compared with diuretics (low certainty).
1 finding from 1 review
Total mortality
Beta‐blockers showed no clear difference in total mortality compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Total cardiovascular disease
Beta‐blockers probably leads to higher total cardiovascular disease compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Stroke
Beta‐blockers probably leads to higher total stroke compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review